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Abstract  
 
Purpose: To evaluate the cost-utility of Vertebroplasty versus conservative therapy 
(Thoracolumbosacral orthosis) for treatment of post-traumatic non-osteoporotic and/or non-
neoplastic fractures. 
 
Materials and Methods: A prospective, randomized, non-blinded, single-center study was carried out 
between 2010 and 2013. The study included 99 patients, aged from 18 years to 70 years, suffering 
from acute non-osteoporotic vertebral fracture. We compared costs and Quality-Adjusted Life Years 
and assessed the Incremental Cost-Effectiveness Ratio for the two arm groups. Health insurance, 
patient and societal perspectives are considered.  
 
Results: For health insurance perspective, total cost was €7,267 for the brace group versus €7,365 for 
the vertebroplasty group (mean difference €75.3; p <0.9). For patient perspective, total cost was 
€5,303 for the brace group and €3,435 for the vertebroplasty group (mean difference €-1,900.7; 
p<0.02). For societal perspective, total cost was €13,071 for the brace group and €14,289 for the 
vertebroplasty group (mean difference €1,165, p <0.36). Differences between groups in QALY were 
non-significant: 0.01 (95% CI -0.01; 0.04 p=0.5). The Incremental Cost-Effectiveness Ratio was €-
12,200 for the health insurance perspective, €159,200 for the patient perspective and €119,466 for 
societal perspective.  
 
Conclusion: The difference in QALYs does not differ between the two groups, but the vertebroplasty 
technique results in significantly lower costs from a patient perspective. From societal and health 
insurance perspectives, we are unable to conclude if the vertebroplasty was more cost-effective than 
Thoracolumbosacral orthosis.  
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practice. 
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1. INTRODUCTION 
 
Traumatic Vertebral fractures represent 14% of verterbral fracture cases and are painful and disabling 
(Mons et al, 2007). With an annual incidence between 19 and 88/100,000 inhabitants in developed 
countries, the people most at risk are active male adults with an average age of 45 years.  
Vertebroplasty is performed with the injection of polymethyl methacrylate resin within the vertebra in 
order to stabilize and reduce pain. Initially used for osteolytic vertebral metastases, myeloma and 
vertebral angioma, this technique has been widely developed (Voormolen and al, 2007; Rousing et al, 
2009; Diamond et al, 2006; Diamond et al, 2003; Ploeg et al, 2006 and Masala and al, 2009) especially 
for osteoporotic fractures even so the results were not unanimous (Rousing et al, 2010; Kallmes et al, 
2009; Müller and al, 2010; Zaryanov and al, 2014 and Klazen and al, 2007). However, vertebroplasty 
for treatment of non-osteoporotic and/or non-neoplastic fractures
 
was poorly supported by the 
scientific literature (Masala and al, 2009 and Knavel and al, 2009) and therefore remains controversial 
(Stadhouder and al, 2008; Hossam, 2015 and Maestretti and al, 2014)  
Thoracolumbosacral orthosis (TLSO) is the established conservative treatment of choice for the 
treatment of post-traumatic fractures (Klazen and al, 2007). 
If the efficacy of vertebroplasty is proved, the efficiency of the adoption of this alternative in a clinical 
practice needs to be estimated. The objective of this study was to assess the cost-utility of 
vertebroplasty compared to TLSO for treatment of non-osteoporotic and/or non-neoplastic fractures.  
 
2. MATERIALS AND METHODS  
2.1. STUDY POPULATION  
This study was based on the findings of the single-center, non-blinded, prospective, randomized trial 
conducted between May 2010 and November 2011 at the Hospital of Clermont-Ferrand, France, 
whose study methods, including the protocol, patient selection and clinical outcome measures were 
available (ClinicalTrials.gov number, NCT01643395). The study included 99 patients aged from 18 to 
70 years suffering from acute (<15 days) Magerl type A non-osteoporotic vertebral fracture including 
28% of patients with at least one A3 burst fracture. Exclusion criteria were as follows: - C1 to T4 
fractures - associated posterior arch fracture - substantial retropulsion of bony fragments (medullary 
canal narrowing superior to 50 % in lumbar and 30% in thoracic spine) – neurological complications - 
head injury with Glasgow Score <15 - long-term painkiller therapy – Local or systemic infection –
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suspected or known malignancy- Coagulation Disorders - Contraindication to general anaesthesia - 
pregnant women – no informed consent obtained. 
The protocol was approved by the institutional review board and the local ethical committee. All 
patients provided written informed consent. 
 
2.2 PROCEDURE  
Vertebroplasty: 
Procedures were performed by one of the three highly experienced Neuroradiologists having 
performed more than 300 procedures each under general anaesthesia. An 11 Gauge needle was 
advanced in the anterior third of the vertebral body. Barium opacified PMMA (Osteopal V Hereus or 
OsteoFirm William Cook Europe, Bjaeverskov, Denmark) was injected under constant lateral 
fluoroscopic control. If no injury or complication, patients were discharged the day after procedure. 
Type and volume of cement injected, cement leakage or procedural complication, were collected after 
each procedure on the e-CRF.  
TLSO: 
A tailored thoracolumbosacral orthosis (TLSO) was required to be worn at all times except when lying 
flat in bed. Compliance in wearing the brace was self-reported by the patient at all relevant follow-up 
periods. The brace was set to be worn for a period of three months along with rehabilitation and 
physiotherapy. 
2.3 MEASUREMENT OF UTILITY    
Outcome measures were performed before randomization and at 1, 3 and 6 months (16; 18). The 
primary endpoint was the quality of life, measured by the Short-Form 36 questionnaire (SF-36) at 
baseline, 1, 3 and 6 months. The SF-36 questionnaire includes 36 questions exploring eight 
dimensions of quality of life. It has been validated in France. This questionnaire has a limited 
application in economic evaluation based upon the criticism that its questions do not rely on individual 
preferences (HAS, 2011).  However, the SF-6D, developed by Brazier and al. (Brazier and al, 1998) 
enables QALYs to be obtained from the SF-36 for use in cost-utility analysis. His algorithm was 
considered as having more rigorous methodological and theoretical bases, and better robustness of 
results (Pickard and al, 2005). Although the SF-6D has not been validated in France (HAS, 2011), in 
the absence of an alternative, we used this scale to estimate QALYs. From utility scores generated, the 
number of QALYs was calculated by multiplying the length spent in health states) by preference 
scores associated with these conditions (HAS, 2011). QALYs gained by the intervention were 
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calculated by adopting the area-under-the-curve method and assuming that patients return after 12 
months (at their level in the inclusion) (Richardson G and Manca, 2004). For each group, the mean 
value was calculated and the average utility of the vertebroplasty group was subtracted from the 
average utility group TLSO. The formula used was as follows (Drummond and al, 2005): 
 
 
where α, α1, α2, α3/ β, β1, β2, and β3 correspond to the length spent in health states at baseline, 1, 3 and 
6 months for vertebroplasty/TLSO group.  
Imbalance in baseline utility must be taken into account for the estimation of mean differential QALY 
by multiple regression methods (Manca and al, 2005). A regression using ordinary least square was 
used (Glick and al, 2007), controlling by sex, age, degree of kyphotic angle and the SF-6D at baseline. 
Selection of variables was made from successive “step by step” iterations, removing variables not 
significantly associated with QALYs. QALYs derived from this model were used in our main analysis.  
 
2.4. COST ESTIMATION  
Data was collected between October 2013 and March 2014. The costing analysis was done following 
the recommendation of the French Health Authority which recommends systematically adopting a 
societal perspective (HAS, 2011; CES, 2003). Direct costs related to care and indirect costs associated 
with cessation of work are considered. However, costs were disaggregated in order to take into 
account the recommendations of other international institutions such as the National Health Service in 
England, Statutory Health Insurance in Germany and Medicare in the United States (Sullivan and al, 
2009; Fricke and Dauben, 2009; NICE, 2013), which recommend adding other perspectives.   
We then added the health insurance, and also the patient perspectives. The cost of production was first 
estimated: the manufacturing cost of the brace in the TSLO arm and the cost of vertebroplasty 
procedure in the second arm. The cost associated with vertebroplasty includes the costs of the injected 
material, the utilization of the neuroradiology room, imaging explorations and biology examinations, 
anesthesia, consultations and acts performed during follow-up. For each technique, the costs of 
hospitalization, imaging and ambulatory care were included. 
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Price data for the cost of brace and the cost of injected material are from the imaging center of the 
hospital of Clermont-Ferrand, for which prices are presented inclusive of VAT. The cost of imaging 
acts, anesthesia and capital facilities were evaluated based on their Relative Cost Index (ICR in 
French). This index expresses the level of mobilization of human and material resources, directly 
necessary to fulfill each act (CES, 2003). The cost of an ICR unit of each component was multiplied 
by the number of necessary ICR corresponding to each patient’s act.  
The cost of biological tests was calculated from the agreed Social Security fee. The cost of single use 
materials and consumables for vertebroplasty was assessed from a standard list, prepared by the 
nursing staff. The cost of hospital stays was evaluated by the French national hospital administrative 
database, Programme de Médicalisation des Systèmes d’Information (PMSI) from cost per the French 
Diagnosis-Related Group (DRG), which uses 2011 data from the French National Scale of Costs 
database. The French National Scale of Costs allows the calculation of complete cost per stay and a 
full cost by DRG. The French DRG is a composite index of diseases, to the extent that a number of 
pathologies are related to a DRG and that the same pathology is found in several DRG (CES, 2003). 
For these reasons, we have adopted the “DRG modified” approach ("DRG aménagé") (CES, 2003) and 
replaced the variable medical costs related to anesthesia, imaging, interventional imaging, laboratory 
tests, consumables, medical devices by observed cost directly attributable to the implementation of oth 
technical. For fixed costs, we used data from the French National Scale of Costs. 
Daily hospital charges and the cost of follow-up (imaging, physiotherapy and nursing home 
consultations) were evaluated from Social Security official tariffs. The cost of a hospital day was 
multiplied by the number of days of hospitalizations for each patient. Similarly, the cost of a 
physiotherapy session, nursing consultation and imaging was multiplied by the number of sessions 
performed for each patient.  
Indirect costs related to the potential loss of production, were evaluated from the average value of a 
daily allowance paid by health insurance under cessation of work (Cour des Comptes, 2012), those 
related to production losses from the commercial sphere were estimated from the daily average wage 
income of the French population (INSEE, 2014).  
The variation in costs and outcomes was undertaken to see if our results are specific to France. All 
costs were estimated in €, and a discount rate of 4% was applied in accordance with the 
recommendations of the HAS (HAS, 2011). 
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2.5. COST-EFFECTIVENESS ANALYSIS  
The mean difference between the two strategies for the total costs and for each cost component was 
tested with the Student’s t-test. A nonparametric bootstrap (2,000 replicates) was used to estimate 
confidence intervals (Glick and al, 2007). To counteract the imbalances between the groups, we 
adopted a generalized linear model (GLM) to estimate the incremental cost (Glick and al, 2007; 
Ramsey and al, 2005; Blough  and al, 1999; Butin and al, 2004; Manning and Mullahy, 2001), 
controlling for age, sex, history of existence of vertebral fractures, cement leakage and severity of 
fracture from the patient's perspective; and the average degree of kyphotic angle, sex, and the SF-6D at 
baseline for the health insurance and society perspectives. Independent variables have been selected 
from successive “step by step” iterations.  
Family function was selected with a Parks Modified-test and goodness of fit test was performed (Glick 
and al, 2007). These tests were the Pearson correlation test and the Hosmer & Lemeshow test 
Modified (for systematic bias in fit on raw scale) and the Pregibon link test (for linearity of response 
on scale of estimation). Costs derived from these models were used in our cost-effectiveness analysis. 
Poisson distribution with a log link were the best fit for the perspective of the health insurance and the 
patient, and the gamma distribution with a log link were the best fit for the perspective of society. The 
incremental cost-effectiveness ratios (ICERs) were calculated as follows:  
 
 
The uncertainty was estimated using a nonparametric bootstrap (O’Brien and Briggs, 2002) generated 
by the "recycled predictions' (Glick and al, 2007). Common in cost-effectiveness analyses for balanced 
data between different groups, this method consists of encoding each patient as if it were part of the 
control group and predicting the results for each individual, then encoding each patient as if they were 
part of the treatment group and predicting the results for each individual. 
Cost-effectiveness acceptability curves were constructed (O’Brien and Briggs, 2002; Black, 1990; 
Fenwick and Byford, 2005). The cost-effectiveness acceptability curve shows the probability that the 
new intervention is cost-effective compared to the former based on the willingness to pay of the 
community (O’Brien and Briggs, 2002). In France, there is no threshold/QALY gained for judging 
whether or not to adopt a new technology. In England, the threshold of €30,000 (£20,000) is generally 
adopted (Weinstein, 2008). In Germany, there is also no official threshold, but some health economists 
use a threshold of €50,000/QALY (Willich and al, 2006). These two thresholds are therefore used in 
our analysis. The cost/QALY represents the willingness to pay. Data analyses were performed with the 
STATA/SE12 (StataCorp LP) software. 
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2.6. SENSITIVITY ANALYSIS 
To assess the robustness of the results, sensitivity analyses were conducted. In the first sensitivity 
analysis, we varied the discount rate to 0% (26);  10% (Coyle and Tolley, 1992) but also 2.5% to take 
into account discussions inside the French Health Authority (HAS) about a potential revision of 
discount rate recommendation and also those of other international institutions. The proper discount 
rate is controversial. Often 3%, 3.5% or 5 % is suggested in international clinical practice guidelines 
(both for costs and outcomes) [Fricke and Dauben, 2009; NICE, 2013; Husereau  and al, 2013). Then, 
we evaluated the effect of different model specifications for the cost estimate. Specifically, we used 
estimates of the difference in costs arising from use of ordinary least squares (OLS) regression in order 
to compare results derived by use of a GLM. 
 
3. RESULTS  
3.1 STUDY POPULATION  
99 patients were included in the analysis (vertebroplasty: 51; TLSO: 48). The mean age and the 
distribution of women was 44.5 years and 41.2% in the vertebroplasty group and 45.3 years and 41.2% 
in TLSO group. Demographic and clinical characteristics are identical between the two groups. In 
74% of patients, one vertebra only was fractured. 
 
3.2 ANALYSIS OF COSTS    
Table 1 shows that due to a higher cost of the intervention (which included the occupation of the room 
and anesthesia); the average hospital cost is greater for the vertebroplasty group (€3,489) than for the 
TLSO group (€502) (bootstrap 95% CI €2,813 to €3,158). The average cost of consumables (single-
use equipment, cement for vertebroplasty group and brace for TLSO group) was 932€ for the TLSO 
group and € 525 for the vertebroplasty group (bootstrap 95% CI €-420 to €-361). However, radiology 
and laboratory exams are not statistically significant between the two groups (bootstrap 95% CI €-35 
to €2). 
From the perspective of health insurance, vertebroplasty is associated with lower cost of patient 
follow-up (consultations physiotherapy and nursing home visits) than the TLSO group (€311 versus 
€606, bootstrap 95% CI €-450 to €-115). However, vertebroplasty is associated with a higher cost of 
imaging act (€134) than the TLSO group (€103.9) (bootstrap 95% CI €18 to €44). The average 
cost/patient was insignificantly different between the two arms (bootstrap 95% CI €-1,048 to €1,207). 
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In contrast, the indirect costs (severance daily paid under cessation of work) was not statistically 
significant between the two groups (€1,652 versus €1,348, bootstrap 95% CI €-1,047 to €407). 
When we consider the patient perspective, the cost of hospital fees was significantly lower (€79.9) for 
the vertebroplasty group than the TLSO group (€1,067), (bootstrap 95% CI €-1,117 to €-851). The 
main reason is that vertebroplasty is a free act and therefore fully covered by health insurance, unlike 
the brace, which is not fully covered by health insurance (80%). The technique of vertebroplasty is 
associated with a lower cost of follow-up (physiotherapy and nursing) (€402.5 versus €207.8, 
bootstrap 95% CI €-300 to €-77). Indirect costs were not statistically significant between the two 
groups (€3,788 versus €3,090, bootstrap 95% CI €-2,401, €934). From the society perspective, the 
average cost/patient was not significantly different between the two groups (€13,072 versus €14,290, 
bootstrap 95% CI €-1367, €3,836). 
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Table1: Estimated mean (SE) cost for patient (univariate analysis), SF-6D utility scores and QALYs 
Cost component    TLSO  
 (N=48) 
(SD) 
Vertebroplasty 
(N=51) 
 (SD) 
Difference  
(95% CI†) 
p for différence 
Occupancy room (1) 426.3  
(0) 
1,131.4  
(235.8) 
703.9  
(644; 1,935) 
<0.001 
Anesthesia (2) 0  
(0) 
1,832.6  
(382) 
1,831.6 
(1,740; 1,941) 
<0.001 
Exam act (3) 145  
(54.3) 
118.3 
(36.7) 
-17.6  
(-35; 2 ) 
0.07 
Consumable (4) 932.5  
(20.7) 
524.8 
(11.3) 
-400.3  
(-420; -361) 
<0.001 
GHMs net of anesthesia, imaging, 
interventional imaging, laboratory tests, 
consumables and medical devices (5) 
1,485.6  
(76) 
1,589.2  
(79.8) 
51.8  
(48,3 ; 55,3) 
0.5 
Health insurance medical device 
reimbursement (6) 
2,540.3  
(144.9) 
1,705.7  
(581.9)  
 -833.5 
 (-966 ; -642) 
<0.001 
Reimbursement of hospitalization by 
health insurance‡  (7) 
4,905.2  
(1,899.2) 
5,571.7 
(2,431.4) 
641.7  
(-181; 1,945) 
0.1 
 
Imaging act (8) 103.9 
(38,1) 
134.2 
(28.5) 
30.5  
(18; 44) 
<0.001 
Follow-up consultation (9) 605.5  
(423,6) 
310.7 
(429.4)  
-292.3 
(-450; -115) 
0.002 
Daily allowance paid (10) 1,652.1  
(2,080) 
1,348.1  
(1,704) 
-318.9 
 (-1,047; 407) 
0.37 
Health insurance cost (11) = 
(1)+(2)+(3)+(4)+ (5) –
(6)+(7)+(8)+(9)+(10) 
7,266.7 
 (3,040) 
7,364.7  
(2,781) 
75.3  
(-1,048; 1,207) 
0.9 
Lump sum at hospital (Hospital charges) 
(12) 
1,067.5 
 (477.6) 
79.9  
(28.4) 
985.8 
 (-1,117; -851) 
<0.001 
Imaging act (13) 45.4 
 (15.1) 
57.6  
(12.2) 
11.9 
 (7; 17) 
<0.001 
Follow-up consultation (14  402.5 
 (282.4) 
207.8 
 (286.2) 
-194.9 
 (-300; -77) 
0.002 
Production loss of market sphere  (15) 3,788 
 (4,770) 
3,090.1  
(3,908) 
-731.2 
(-2,401; 934) 
0.4 
Patient cost (16)= (12)+(13)+(14)+(15) 5,303.4 
 (4,875.3) 
3,435.4 
 (3,884.8) 
-1,900.7 
 (-3,563; -218) 
0.02 
Society cost  
(18)=(11)+(12)+(17) 
13,071.9 
 (7,606) 
14,289.5 
 (5,851.1) 
1,165 
 (-1,367; 3,836) 
0.36 
SF-6D     
Baseline (SD) 0.670 (.158)   0.689 (0.13)   
One month (SD) 0.527 (0.08) 0.578 (0.09)   
Three month (SD) 0.605 (0.01) 0.628 (0.11)   
Six month (SD) 0.649 (0.11) 0.695 (0.12)   
QALY 
 Univariate analysis   0,445  
(0.008) 
0,458  
(0.01) 
0,013 -0.0133 ; 0.0407 
 Multivariate analysis  0.440  
(0.009) 
0.455  
(0.01) 
0.015 -0.0105 ; 0.0442 
†CIs estimated using 2,000 non-parametric bootstrapping replicates. TLSO: Thoracolumbosacral orthosis 
Études et Documents n° 34, CERDI, 2015 
 
12 
 
 
3.3 QALYS   
Table 1 shows the SF-6D scores for each arm at baseline and at one, three and six months. The 
average QALYs (SD) were estimated at 0.440 (SD=0.009) for the TLSO group and 0.455 QALYs 
(SD=0.01) for the vertebroplasty group. The difference in QALYs during the six months of the study 
was not statistically significant between the two groups (bootstrap 95% CI -0.0105 to 0.0442). We find 
similar results for the univariate analysis (bootstrap 95% CI 0.0133, 0.0407). 
 
3.4 INCREMENTAL COST-EFFECTIVENESS RATIO   
The ICER were €-12,200 (-183/0,015) for the health insurance perspective, €159,200 for the patient 
perspective (2,388/0,015) and €119,466 (1,792/0,015) for the society perspective (Table 2).  
 
Tableau 2: Incremental cost, incremental QALY and ICER vertebroplasty versus TLSO, main analysis (4% of 
discount rate) 
Perspective  Incremental cost  
(€, 95 % CI†) 
Incrémental Effect 
(QALY, 95% CI†) 
ICER Lower 
confident 
limit 
Upper 
confident limit 
% of acceptability  
€20,000  € 50,000  
Health 
insurance 
-183 (-1,549; 1,165  0.015 (-0.01;0,04) -12,200 Undefined  72.5% 81.3% 
Patient -2,388 (4,456; -376 0.015 (-0.01;0,04) -159,200 181,049 -20,829 99.8% 99.6% 
Society 1,792 (-1,890; 5,542 0.015 (-0.01;0,04) 128,142 Undefined  18.3% 28.2% 
†CIs estimated using 2,000 non-parametric bootstrapping replicates; ICER: Incremental Cost-Effectiveness Ratio; TLSO: 
Thoracolumbosacral orthosis 
 
Figures 1 show the results of the bootstrap procedure plotted on a cost-effectiveness plane. These 
figures plot the differences in costs and differences in QALYs observed in the 2000 bootstrap 
replicates from which acceptability curves were plotted (Figures 2). From a health insurance 
perspective, the dispersions are such that no 95% CI for the ratio could be identified, which means that 
we can be 95% confident that the two strategies differ from each other. 
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Figure 1 : Cost-effectiveness planes for patient, health insurance and societal perspective 
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-7
5
4
6
.8
7
3
-4
8
6
7
.1
0
4
-2
1
8
7
.3
3
5
4
9
2
.4
3
4
D
iff
e
re
n
ce
 in
 C
o
st
-.0475811 -.0171133 .0133545 .0438224 .0742902
Difference in Effect
Bootstrap estimation Lower_confident
Upper_confident 
-2
0
0
0
-1
0
0
0
0
1
0
0
0
2
0
0
0
3
0
0
0
D
iff
e
re
n
ce
 in
 C
o
st
-.04 -.02 0 .02 .04 .06
Difference in Effect
 
Bootstrap evaluation of incremental costs and QALYS between            Bootstrap evaluation of incremental costs and QALY 
 vertebroplasty group and TLSO group for patient perspective.              between vertebroplasty group and TLSO group for health insurance     
perspective.  ICER = €159,200 ; 95% CI : undefined           ICER = €199,066 €; 95% CI: 181,049; -20,829. 
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      Bootstrap evaluation of incremental costs and QALYS between 
      vertebroplasty group and TLSO group for society perspective. 
      ICER = €119,466 ; 95% CI : undefined 
 
Acceptability curves (Figures 2) provide a more complete understanding of the degree of confidence 
that we can have in the comparison between strategies. From the patient’s perspective, the 
acceptability curve shows that for a willingness to pay of €20,000 there was a 99.8% chance that the 
vertebroplasty is more cost-effective than the TLSO and a 99.6% (of) chance that the vertebroplasty is 
more cost-effective than the TLSO for willingness to pay of €50,000. However, from a health 
insurance and societal perspective, the acceptability curve does not cross the acceptability of 2.5% and 
97.5% levels, we cannot conclude the superiority of one or other technique.  
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Figure 2: Cost-effectiveness acceptability curves for health insurance, patient and societal perspectives 
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The results of our sensitivity analyses are shown in Annex (Table A1 to A3). Modifications in the 
models’ specification do not change our results, whatever the discount rate. Specifically, from the 
perspective of society, the 95% CI were undefined for all models, and acceptability curves remain 
similar.  
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4. DISCUSSION  
Our objective was to assess the cost-utility of vertebroplasty in the context of post-traumatic vertebral 
fractures. This is the first study analysing the cost-utility of this technique versus TLSO in the context 
of post-traumatic vertebral fractures. Literature about this technique focuses more on the osteoporotic 
fractures (Voormolen  and al, 2007; Rousing  and al, 2009; Diamond  and al, 2006; Diamond  and al, 
2003; Ploeg and al, 2006; Masala  and al, 2009; Klazen and al, 2010)
 
and many of them analyze the 
vertebroplasty versus kyphoplasty method (Svedbom  and al, 2013; Fritzell and al, 2011). 
Following the French Health Authority recommendations, which recommend a societal perspective; 
we have deliberately chosen to disaggregate perspectives (health insurance, patients, and society) to 
separate their respective costs and to include recommendations from other institutions for economic 
evaluations: health system or payer perspective (National Health Service in England, Statutory Health 
Insurance in Germany and Medicare in the United States). 
 
Vertebroplasty technique requires higher intervention cost (€2,964) than TLSO (€426). That makes 
sense insofar as vertebroplasty requires expensive equipment and consumables, unlike the TLSO, for 
which the main expense is the brace itself. However, vertebroplasty was less costly in radiology exams 
at baseline, where a significant, but small, difference of €17 is observed. Moreover, the costs of 
follow-up were also lower for vertebroplasty (€517.9) than for TLSO (€1,009.4), where a difference of 
€487 is observed. However, although the duration of work cessation was more important for the TLSO 
arm (116 days) than for vertebroplasty (82 days), no significant differences in indirect costs were 
observed. 
The idea of using threshold values in decision-making encountered some criticism, such as, among 
others, the risk of uncontrolled growth of health care spending. However, the thresholds represent 
society’s willingness to pay for health care, and for that, this (decision) rule is considered more 
appropriate for policymakers (Eichler and al, 2004). In France, no threshold value is given by the 
competent authorities, so we took two different thresholds: €20,000 and €50,000.  
Our analysis shows mixed results depending on the chosen perspective. For the hospital perspective, 
we concluded in favor of TLSO; conversely, from the patient’s point of view, vertebroplasty is the 
dominant strategy. This is explained by the fact that the patient needs a longer period of bed rest with 
TLSO than for vertebroplasty which, induces faster recovery and a lower cost of follow-up. As there is 
a gain for the patient, an argument can be provided that health insurance may increase the budgetary 
allocation. On the other hand, an argument can be given that complementary health insurance may 
assume the cost for the patient to the extent that the cost of vertebroplasty is less than the TLSO. 
Études et Documents n° 34, CERDI, 2015 
 
16 
 
 
In contrast, no difference in the relative cost-effectiveness of the vertebroplasty compared with the 
TLSO appears from a health insurance and society perspective. For these last two perspectives, the 
differences in costs and the differences in QALYs between the two groups were not significant. 
However, despite these not significant results, we nevertheless performed an economic analysis, 
insofar as it is possible to have a greater confidence in the joint outcome of costs and QALYs than 
about either of the outcomes individually (Glick and al, 2001). For these two perspectives, we are 
therefore unable to determine whether vertebroplasty is more effective than the TLSO. 
Sensitivity analysis does not change the results. The disaggregated results allow us to choose the 
desired perspective, depending on the institution (societal for France, health system or payer 
perspective for England, Germany or the United States). The first drawback of our study is the 
exclusion of costs (presenteeism costs, patient’s family costs...) although several studies show a 
significant impact on the results (Pauly, 2008; Collins and al, 2005; Burton, 2005) and which would 
have allowed us to have a more complete picture of the cost analysis. This non-inclusion can be 
explained by the fact that the clinical study had previously been designed without economic 
evaluation, the choice of integrating a medico-economic component has come at the end of the clinical 
study. We have thus not been able to establish all the elements necessary for a complete analysis. 
Similarly, the study of follow-up costs does only limit to hospital prescriptions, omitting any eventual 
prescriptions made by the family doctors, but also supplementary cessation of work. In the context of 
cessation of work, we hypothesized that patients returned to full-time employment, or it is possible 
that some have benefited from part-time work arrangements. The second drawback concerns the 
QALYs calculation. We used the Brazier al. algorithm of converting data from SF-36. Despite its 
rigorous theoretical and methodological bases (Pickard and al, 2005), the weighting function for 
assigning a weight to each of these states was calculated from the United Kingdom population, which 
does not necessarily reflect the preferences of the French population. The QALYs via VAS could be 
calculated, however, many health economists considering that VAS are not considered as utilities 
insofar as it does not require explicit choice and has scales undesirable properties (Nord, 1991). The 
third drawback is the fact that the trial was not blind, patients knew which treatment they were 
receiving. Knowledge of treatment assignment probably influenced patients' responses during 
evaluations. Finally, the six month follow-up period was too short. A much longer evaluation of these 
two strategies especially in terms of costs (re-hospitalization, sick leave...) should be considered.  
 
In conclusion, our analysis shows mixed results depending on the chosen perspective. The choice of 
perspective will depend on what the government wants to give preference to, namely the financial 
resources of patients, to the detriment of the budgetary impact, or consider that budgetary impact is 
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most important. In France, where the excess for the patient is low (approximatively €290) the 
government's position will not favor this approach. In constrast, in the United States, health-related 
costs are very high and the excess for the patient is important, the government's position could be 
different due to excessive coverage. 
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Annex 
Tableau A1: Incremental cost, incremental QALY and ICER vertebroplasty versus TLSO, univariate analysis  
Perspective  Incremental cost (€, 95 % CI†) Incrémental Effect 
(QALY, 95% CI†) 
ICER Lower confident 
limit 
Upper confident limit % of acceptability  
€20,000  € 50,000  
Discount rate 0% 
Health insurance  -94.2 (-1,087; 1,333)  0.014 (-0.01;0.06) -6,729 Undefined  61% 72.7% 
Patient -2,008 (-3,764; -230) 0.014 (-0.01;0.06) -143,428 93,652 -13,920 99.3% 99.2% 
Society 1,138 (-1,544; 3,971) 0.014 (-0.01;0.06) 81,286 Undefined  26.9% 39.4% 
Discount rate 2.5% 
Health insurance  -92.5 (-1,042 ; 1,282) 0.016 (-0.013 ; 0.05) -5,781 Undefined 61.2% 73.2% 
Patient -1,339.8 (3,636; -222) 0.016 (-0.013 ; 0.05) -83,687 93,652 -13,920 99.3 % 99.2% 
Society  0.016 (-0.013 ; 0.05) 72,625 Undefined 24.4% 37.2% 
Discount rate 4% 
Health insurance -75.3 (-1,048; 1,207) 0.016 (-0.013 ; 0.04) -4,706 Undefined  61.3% 73.2% 
Patient -1,901 (-3,563; -218) 0.016 (-0.013 ; 0.04) -118,812 93,652 -13,920 99.3% 99.2% 
Society  1,165 (-1,367; 3,836) 0.016 (-0.013 ; 0.04) 72,812 Undefined  24.4% 37.2% 
Discount rate 10% 
Health insurance -65.4 (-978; 1,146) 0.016 (-0.009; 0.04) -4,087 Undefined  61.9% 73.3% 
Patient -1,757 (-3,294; -133) 0.016 (-0.009; 0.04) -109,812 93,652 -13,920 99.3% 99.2% 
Society 1,265 (-1,067; 3,713) 0.016 (-0.009; 0.04) 79,072 Undefined  21.3% 32.9% 
†CIs estimated using 2,000 non-parametric bootstrapping replicates.  
ICER: Incremental Cost-Effectiveness Ratio 
TLSO: Thoracolumbosacral orthosis 
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Tableau A2: Incremental cost, incremental QALY and ICER vertebroplasty versus TLSO, multivariate analysis GLM  
Perspective  Incremental cost (€, 95 % CI†) Incrémental Effect 
(QALY, 95% CI†) 
ICER Lower confident 
limit 
Upper confident limit % of acceptability  
€20,000  € 50,000  
Discount rate 0% 
Health insurance -185 (-1,616; 1,236  0.016 (-0.01;0.06) -11,562 Undefined  81.3% 81,3% 
Patient -2,461 (-4,708;398) 0.016 (-0.01;0.06) -153,813 181,050 -20,829 99.8% 99.6% 
Society  1,787 (-2,094; 5,739) 0.016 (-0.01;0.06) 111,688 Undefined  23.6% 27.1% 
Discount rate 2.5% 
Health insurance -179 (-1,542; 1,075) 0.014 (-0.009;0.04) -11,187 Undefined  72.8% 81.2% 
Patient -2,378 (-4,119; -348) 0.014 (-0.009;0.04) -148,625 181,049 -20,829 99.8% 99.6% 
Society 1,792 (-1,837; 5,496) 0.014 (-0.009;0.04) 112,000 Undefined  22.4% 32.3% 
Discount rate 4% 
Health insurance -176 (-1,573;1,214)  0.016 (-0.01;0.06) -11,000 Undefined  73.1% 81,7% 
Patient -3,098 (-4,708;398) 0.016 (-0.01;0.06) -193,625 181,050 -20,829 99.8% 99.5% 
Society  1,387 (-2,094; 5,739) 0.016 (-0.01;0.06) 86,687 Undefined  29% 39.5% 
Discount rate 10% 
Health insurance -175 (-1,417; 1,056) 0.014 (-0.009;0.04) -12,857 Undefined  72.5% 81.3% 
Patient -2,032 (-3,788; -308) 0.014 (-0.009;0.04) -173,293 181,049 -20,829 99.8% 99.6% 
Society 1,407 (-2,112; 4,841) 0.014 (-0.009;0.04) 100,500 Undefined  24.1% 33.1% 
†CIs estimated using 2,000 non-parametric bootstrapping replicates 
ICER : Incremental Cost-Effectiveness Ratio 
TLSO: Thoracolumbosacral orthosis 
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Tableau A3: Incremental cost, incremental QALY and ICER vertebroplasty versus TLSO, multivariate analysis OLS 
Perspective  Incremental cost (€, 95 
% CI†) 
Incremental effect 
(QALY, 95 % 
CI†) 
ICER Lower confident limit Upper confident 
limit 
% d’acceptabilité  
€20,000  €50,000  
Discount rate 0% 
Health 
insurance 
-176 (-1,573 ; 1,114) 0.016 (-0.01;0.06) -11,000 Undefined  73.1% 81.7% 
Patient -3098 (-2,882;  -331)  0.016 (-0.01;0.06) 175,375 173,293 -18,100 99.8% 99.5% 
Society 1,387 (-2,365 ; 5,070) 0.016 (-0.01;0.06) 86,688 Undefined  29% 39.5% 
Discount rate 2.5% 
Health 
insurance 
-172 (1,517 ; 1,166) 0.014 (-0.009;0.04) 10,731 Undefined 73.3% 81,8% 
Patient -2,243 (-4,181; -340) 0.014 (-0.009;0.04) -140,187 173,293 -18,100 99.8% 99.5% 
Society 1,401 (-2,206; 4,927)  0.014 (-0.009;0.04) 87,562 Undefined 28% 38.1% 
Discount rate 4% 
Health 
insurance 
-175.5 (-1,505 ; 1,147)  0.016 (-0.01;0.06) -12,536 Undefined  73.5% 82% 
Patient -2,198 (-4,097; -333) 0.016 (-0.01;0.06) -157,000 173,293 -18,100 99.8% 99.5% 
Society 1,403 (-2,161 ; 4,882) 0.016 (-0.01;0.06) 100,214 Undefined 27.6% 37.4% 33.9% 
Discount rate 10% 
Health 
insurance 
-174.7 (-1,417 ; 1,056)  0.014 (-0.009;0.04) -12,479 Undefined  73.8% 82.1% 
Patient -2,032 (-3,788; 308) 0.014 (-0.009;0.04) -145,142 173,293 -18,100 99.8% 99.5% 
Society 1,407 (-2,112 ; 4,841) 0.014 (-0.009;0.04) 106,214 Undefined 24.1% 33.9% 
†CIs estimated using 2,000 non-parametric bootstrapping replicates 
ICER : Incremental Cost-Effectiveness Ratio 
TLSO: Thoracolumbosacral orthosis 
 
 
